<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731701</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.HAEM89-005</org_study_id>
    <nct_id>NCT04731701</nct_id>
  </id_info>
  <brief_title>Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)</brief_title>
  <acronym>Hemo-FAST</acronym>
  <official_title>Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantar Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the newly developed Hemophilia Functional Ability&#xD;
      Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess&#xD;
      patient-reported functional mobility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to validate the newly developed Hemophilia Functional Ability&#xD;
      Scoring Tool (Hemo-FAST), which is a fast and simple scoring in haemophilia able to assess&#xD;
      patient-reported functional mobility for adult haemophilia patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST).</measure>
    <time_frame>Baseline</time_frame>
    <description>Statistical analysis to confirm the psychometric validation of the Hemo-FAST questionnaire</description>
  </primary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hemophilia Joint Health Score (HJHS)</intervention_name>
    <description>Joint examination with Hemophilia Joint Health Score (HJHS)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be enrolled from 10-15 haemophilia treatment centres (HTCs) across France.&#xD;
        The lower age limit of 18 years has been chosen because Hemo-FAST was developed to be used&#xD;
        among the adult population. Age is an important contributor to the development of joint&#xD;
        damage. Enrolment will therefore be targeted so that there will be similar numbers of&#xD;
        patients enrolled across three age groups: 18-29, 30-44 and ≥ 45-years old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:A patient must fulfil the following criteria in order to be included in&#xD;
        the study:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Diagnosis of haemophilia A or B.&#xD;
&#xD;
          3. Capable of completing the study Patient-Reported Outcome (PRO) questionnaires in&#xD;
             French.&#xD;
&#xD;
          4. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following criteria will exclude a patient from inclusion in the&#xD;
        study:&#xD;
&#xD;
          1. Joint replacement within last 6 months.&#xD;
&#xD;
          2. Patients with a non-resolved joint or muscle bleeding event at the enrolment visit or&#xD;
             ≤ 7 days prior to the enrolment visit.&#xD;
&#xD;
          3. Patients with comorbid illnesses such as juvenile arthritis, muscular dystrophy,&#xD;
             neurologic illness/cognitive impairment, or other illnesses that may independently&#xD;
             affect HJHS and Hemo-FAST scores and/or limit the ability of the patient to&#xD;
             participate in the study as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per Hedlund</last_name>
    <phone>+46 8 697 2000</phone>
    <email>per.hedlund@sobi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Orphan Biovitrum Clinical site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

